Valion Bio VBIO
NASDAQ VBIO
$0.54 +0.02 (+3.85%)
At close: Nov 13, 2026 · 4:00 PM EST

Valion Bio (VBIO) Gains (Losses) on Sale of Assets & Investments (2025)

Updated

Valion Bio's Non Operating Investment Income was -$117,000 in Q3 2025.

Analysis

Valion Bio (VBIO) Gains (Losses) on Sale of Assets & Investments (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn -
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn -
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn -
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn -
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn -
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn -
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn -
10 Valion Bio 73,008.00 -25.39 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -117,000.00
API Access

Valion Bio Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=VBIO&period=max&api_key=YOUR_API_KEY